Participants/Descriptive Data:
Excluding 983 of 1,078 SARS-CoV-2 positive children during our study period who were not considered immunocompromised, there were 91 children who met inclusion and exclusion criteria. The sociodemographic and clinical characteristics of children, classified as oncology patients versus those on other immunosuppressive agents, are shown in Table 1. The median age of children was 15.5 years (IQR 8-18 yrs), 64% were male, and 53% of children were white, with 43% being Hispanic or Latinx. Most children (67%) were tested in outpatient settings, and 58% of children were asymptomatic at the time of their first positive test. A higher proportion of children with an oncologic diagnosis were male, but otherwise there were no significant differences in demographics, hospitalization or testing indication between children with oncologic diagnoses and children with other immunocompromising conditions.
The median number of repeat tests among children in our cohort was 2 (IQR 0,4). The number of SARS-CoV-2 PCR tests and results for children in our cohort with more than 1 test are shown in Figure 1. Children with an oncologic diagnosis were more likely to have >1 SARS –CoV-2 PCR test and complete blood count testing within 72 hours of their initial test. Children with an oncologic diagnosis were more likely to have a lower median ALC (550 vs 1015, p = 0.039) compared with children with other immunocompromising conditions.